On Monday, in the course of current trade, Shares of KBR, Inc. (NYSE:KBR), climbed 1.04%, and is now trading at $17.44.
KBR, has been awarded a cost plus fixed fee task order in the Arabian Peninsula under the Logistics Civil Augmentation Program (LOGCAP) IV contract.
For this task order, KBR will provide logistics, operations, and maintenance support for the U.S. Army across eight sites in Kuwait. Upon the direction of the U.S. Government, services can be expanded to other countries in the Arabian Peninsula region. This work is expected to be performed over one base year with three option years. Requirements will focus on facilities management, theatre transportation and movement control, waste and sewage management, and airfield operations services.
KBR is also currently executing LOGCAP IV task orders in United Arab Emirates and Iraq. “We are excited to be a part of this significant program and to continue to grow and maintain a substantial presence in the Middle East Region,” said Andrew Pringle, President of KBR’s Government Services Segment.
KBR, Inc. operates as an engineering, construction, and services company worldwide. The company operates through three segments: Technology & Consulting, Engineering & Construction, and Government Services.
During an Afternoon trade, Shares of Intrexon Corp (NYSE:XON), dipped -3.58%, and is now trading at $45.08.
Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, declared it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company’s Phase 2 study for SGX942. SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Consistent with prior guidance, Soligenix anticipates reporting preliminary results in the fourth quarter of 2015.
This Phase 2 study is a randomized, double-blind, dose-ranging, placebo-controlled trial, initially set to enroll approximately 75 subjects across 3 SGX942 dose groups and a placebo group, focused on demonstrating the safety and biologic activity of SGX942 in patients with cancer of the mouth and oropharynx who often experience debilitating oral mucositis as a consequence of their treatment with CRT. Following the DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include at least an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug’s potential effect and to inform final dose selection in this patient population. The efficacy assessment is the comparison of the incidence and/or duration of both ulcerative and severe oral mucositis throughout the subjects’ 7 week course of CRT and for an additional 4 weeks thereafter.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components.
Shares of Oclaro, Inc. (NASDAQ:OCLR), during its Monday’s current trading session fell -1.44%, and is now trading at $2.74.
Oclaro, declared that management is scheduled to host meetings on August 25, 2015 with the investment community at the Jefferies Semiconductors, Hardware & Communications Infrastructure Summit, which will be held at The Ritz-Carlton Chicago.
Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in telecom networks.
Finally, NASDAQ OMX Group, Inc. (NASDAQ:NDAQ), lost -0.76% Monday.
Champions Oncology, providers of an innovative oncology drug development platform used by nearly 100 biopharmas, including many of world’s largest pharmaceutical companies, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Joel Ackerman, Chief Executive Officer will ring the Closing Bell.
On Tuesday, September 1, 2015 – 3:45 p.m. to 4:00 p.m. ET, Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
The NASDAQ OMX Group, Inc. provides trading, clearing, exchange technology, regulatory, securities listing, information, and public company services worldwide. It operates in four segments: Market Services, Listing Services, Information Services, and Technology Solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
